Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.

convolutional neural network deep learning lymphoma total metabolic tumor volume

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
06 Feb 2022
Historique:
received: 31 12 2021
revised: 28 01 2022
accepted: 01 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

The total metabolic tumor volume (TMTV) is a new prognostic factor in lymphomas that could benefit from automation with deep learning convolutional neural networks (CNN). Manual TMTV segmentations of 1218 baseline 18FDG-PET/CT have been used for training. A 3D V-NET model has been trained to generate segmentations with soft dice loss. Ground truth segmentation has been generated using a combination of different thresholds (TMTVprob), applied to the manual region of interest (Otsu, relative 41% and SUV 2.5 and 4 cutoffs). In total, 407 and 405 PET/CT were used for test and validation datasets, respectively. The training was completed in 93 h. In comparison with the TMTVprob, mean dice reached 0.84 in the training set, 0.84 in the validation set and 0.76 in the test set. The median dice scores for each TMTV methodology were 0.77, 0.70 and 0.90 for 41%, 2.5 and 4 cutoff, respectively. Differences in the median TMTV between manual and predicted TMTV were 32, 147 and 5 mL. Spearman's correlations between manual and predicted TMTV were 0.92, 0.95 and 0.98. This generic deep learning model to compute TMTV in lymphomas can drastically reduce computation time of TMTV.

Identifiants

pubmed: 35204515
pii: diagnostics12020417
doi: 10.3390/diagnostics12020417
pmc: PMC8870809
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Comput Biol Med. 2014 Jul;50:76-96
pubmed: 24845019
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1463-1464
pubmed: 29651546
Br J Radiol. 2021 Nov 1;94(1127):20210448
pubmed: 34379496
Front Oncol. 2021 Mar 09;11:638182
pubmed: 33768000
Blood. 2011 Jul 7;118(1):37-43
pubmed: 21518924
J Digit Imaging. 2020 Aug;33(4):888-894
pubmed: 32378059
J Nucl Med. 2021 Mar;62(3):332-337
pubmed: 32680929
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1362-1370
pubmed: 33097974
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
PLoS One. 2015 Oct 16;10(10):e0140830
pubmed: 26473950
Blood. 2018 Mar 29;131(13):1456-1463
pubmed: 29437590
Blood. 2021 Apr 29;137(17):2307-2320
pubmed: 33211799
Lancet Oncol. 2019 Feb;20(2):202-215
pubmed: 30658935
Haematologica. 2020 Dec 17;107(1):221-230
pubmed: 33327711
N Engl J Med. 2018 Sep 6;379(10):934-947
pubmed: 30184451
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43
pubmed: 24811577
Br J Haematol. 2020 Apr;189(1):84-96
pubmed: 31702836
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1113-22
pubmed: 24570094
J Nucl Med. 2021 Jan;62(1):30-36
pubmed: 32532925

Auteurs

Wendy Revailler (W)

Centre de Recherche Clinique de Toulouse, Team 9, 31100 Toulouse, France.
Institut Universitaire du Cancer de Toulouse, Institut Claudius Regaud, Nuclear Medicine, 1 Avenue Joliot Curie, 31000 Toulouse, France.

Anne Ségolène Cottereau (AS)

Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Nuclear Medecine, René Descartes University, 75014 Paris, France.

Cedric Rossi (C)

CHU Dijon, Hematology, 10 Boulevard Maréchal De Lattre De Tassigny, 21000 Dijon, France.

Rudy Noyelle (R)

Thales Services, 31400 Toulouse, France.

Thomas Trouillard (T)

Centre de Recherche Clinique de Toulouse, Team 9, 31100 Toulouse, France.
Institut Universitaire du Cancer de Toulouse, Institut Claudius Regaud, Nuclear Medicine, 1 Avenue Joliot Curie, 31000 Toulouse, France.

Franck Morschhauser (F)

ULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, CHU Lille, 59000 Lille, France.

Olivier Casasnovas (O)

CHU Dijon, Hematology, 10 Boulevard Maréchal De Lattre De Tassigny, 21000 Dijon, France.

Catherine Thieblemont (C)

Hemato-Oncology Unit, Saint-Louis University Hospital Center, Public Hospital Network of Paris, 75010 Paris, France.

Steven Le Gouill (SL)

Department of Hematology, Nantes University Hospital, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, 44000 Nantes, France.

Marc André (M)

Department of Hematology, Université catholique de Louvain, CHU UcL Namur, 5530 Yvoir, Belgium.

Herve Ghesquieres (H)

Department of Hematology, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.

Romain Ricci (R)

LYSARC, Centre Hospitalier Lyon-Sud, 165 Chemin du Grand Revoyet Bâtiment 2D, 69310 Pierre-Bénite, France.

Michel Meignan (M)

LYSA Imaging, Henri Mondor University Hospital, AP-HP, University Paris East, 94000 Créteil, France.

Salim Kanoun (S)

Centre de Recherche Clinique de Toulouse, Team 9, 31100 Toulouse, France.
Institut Universitaire du Cancer de Toulouse, Institut Claudius Regaud, Nuclear Medicine, 1 Avenue Joliot Curie, 31000 Toulouse, France.

Classifications MeSH